<qa>  What is the final dose to be used in the Panel 2?This is a two-part Phase 1 study consisting of a dose escalation part Part 1 and a TQT part Part 2, performed in two separate panels Panels 1 and 2. Panel 1 will be a double blind neither the researchers nor the participants know what treatment the participant is receiving, randomized study medication assigned to participants by chance, placebo controlled dose escalation study in healthy participants to determine the safety, tolerability and pharmacokinetics of ALS-008176 after administration of single doses of 1500 milligrams mg, 2500 mg and 3000 mg under fasted conditions. The final dose to be used in the Panel 2 will be determined based on the results of this dose escalation part. An interim analysis will be conducted on Panel 1 to select the dose for Panel 2. Panel 2 will be a double blind, double dummy, randomized, 3 period crossover the same medications provided to all participants but in different sequence, placebo and positive controlled study to evaluate the effect of ALS-008176 on the QTQTc interval in healthy participants. Participants safety will be monitored throughout the study. 